PriceTargets.com logo

Silence Therapeutics - SLN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.25
  • Forecasted Upside: 602.38%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.30 As of 03/30/2023 01:00 AM ET
▼ -0.1 (-1.56%)

This chart shows the closing price for SLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silence Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLN

Analyst Price Target is $44.25
▲ +602.38% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is $44.25, with a high forecast of $80.00 and a low forecast of $18.00. The average price target represents a 602.38% upside from the last price of $6.30.

This chart shows the closing price for SLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Silence Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023HC WainwrightReiterated RatingBuy$80.00Low
3/16/2023Chardan CapitalLower TargetBuy$29.00 ➝ $26.00Low
1/26/2023Robert W. BairdBoost Target$50.00 ➝ $53.00Low
12/9/2022Morgan StanleyInitiated CoverageEqual Weight$18.00Low
12/6/2022HC WainwrightLower TargetBuy$95.00 ➝ $80.00Low
11/17/2022Chardan CapitalLower TargetBuy$33.00 ➝ $29.00Low
3/31/2022Chardan CapitalInitiated CoverageBuy$33.00Low
3/22/2022HC WainwrightLower TargetBuy$100.00 ➝ $95.00High
11/23/2021HC WainwrightReiterated RatingBuy$99.00Low
10/22/2021William BlairReiterated RatingBuyHigh
4/30/2021William BlairReiterated RatingBuyN/A
11/18/2020BTIG ResearchInitiated CoverageBuyLow
10/27/2020William BlairReiterated RatingOutperformLow
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Silence Therapeutics logo
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $6.30
Low: $6.01
High: $6.94

50 Day Range

MA: $11.39
Low: $6.40
High: $13.50

52 Week Range

Now: $6.30
Low: $6.01
High: $21.32

Volume

25,764 shs

Average Volume

42,893 shs

Market Capitalization

$188.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Silence Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Silence Therapeutics in the last twelve months: Chardan Capital, HC Wainwright, Morgan Stanley, and Robert W. Baird.
View the latest analyst ratings for SLN.

What is the current price target for Silence Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Silence Therapeutics in the last year. Their average twelve-month price target is $44.25, suggesting a possible upside of 602.4%. HC Wainwright has the highest price target set, predicting SLN will reach $80.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $18.00 for Silence Therapeutics in the next year.
View the latest price targets for SLN.

What is the current consensus analyst rating for Silence Therapeutics?

Silence Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLN will outperform the market and that investors should add to their positions of Silence Therapeutics.
View the latest ratings for SLN.

What other companies compete with Silence Therapeutics?

Other companies that are similar to Silence Therapeutics include Inozyme Pharma, Zevra Therapeutics, Ovid Therapeutics, Fulcrum Therapeutics and Selecta Biosciences. Learn More about companies similar to Silence Therapeutics.

How do I contact Silence Therapeutics' investor relations team?

Silence Therapeutics' physical mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The company's listed phone number is 44-0-20-3457-6900. The official website for Silence Therapeutics is www.silence-therapeutics.com. Learn More about contacing Silence Therapeutics investor relations.